Cara Therapeutics Inc T.CARA

Primary Symbol: CARA

Healthcare Cannabis

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

NDAQ:CARA - Post by User

Cara Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by SkyeCairnson Nov 27, 2015 1:41pm

277 Views

Post# 24332287

Offering

The secondary offering at the price(34.75) and in the amount that it was is going to push and keep this stock down for the rest of the year. I think this is poor mgmt. They (Cara) should have either bought the private shares themselves or they (the family) should have sold the shares over a longer period of time. The market is going to take quite a bit of time to digest these shares.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China